International Assets Investment Management LLC Raises Stake in Bristol Myers Squibb Company (NYSE:BMY)

International Assets Investment Management LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 16.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,414 shares of the biopharmaceutical company's stock after purchasing an additional 6,041 shares during the period. International Assets Investment Management LLC's holdings in Bristol Myers Squibb were worth $2,648,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Pinney & Scofield Inc. bought a new position in Bristol Myers Squibb during the 4th quarter worth $25,000. Park Square Financial Group LLC acquired a new position in Bristol Myers Squibb in the fourth quarter valued at about $26,000. Fairway Wealth LLC acquired a new stake in Bristol Myers Squibb during the fourth quarter worth about $28,000. Transce3nd LLC bought a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $28,000. Finally, Global Wealth Strategies & Associates increased its stake in shares of Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Down 0.6%

Shares of NYSE:BMY traded down $0.30 during mid-day trading on Wednesday, hitting $46.73. 9,010,197 shares of the company traded hands, compared to its average volume of 12,959,079. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. The stock has a 50-day moving average price of $48.06 and a two-hundred day moving average price of $54.16. Bristol Myers Squibb Company has a 12-month low of $39.35 and a 12-month high of $63.33. The stock has a market cap of $95.10 billion, a P/E ratio of 17.50, a P/E/G ratio of 1.39 and a beta of 0.38.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. Bristol Myers Squibb's quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the company posted ($4.40) earnings per share. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.31%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is 92.88%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction that occurred on Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.09% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on BMY. William Blair reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. UBS Group dropped their target price on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $55.00 price target on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $58.00.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.